Alnylam Pharmaceuticals EV / EBIT TTM
Alnylam Pharmaceuticals EV / EBIT TTM Chart
Alnylam Pharmaceuticals Historical EV / EBIT TTM DataPro Data Export
There is no data for the selected date range.
About EV / EBIT
Enterprise value of a company divided by its Earnings Before Interest Taxes (TTM).
EV/EBIT answers the question "What is a company being valued per each dollar of EBIT?" A high (low) EV/EBIT mean the company is potentially overvalued (undervalued).
EV/Financial Metrics are often used by analysts to quickly look at a company's valuation multiples. All things being equal, the lower this ratio is, the better.
Other similar metrics include :
EV/EBITDA : How much is each dollar of EBITDA worth to investors?
EV/Revenues : Or each dollar of Revenues?
EV/Free Cash Flow : Or each dollar of FCF?
For more information on evaluating valuation multiples similar to this, please see our original white paper research : Making Sense Of Valuation Multiples.
View EV / EBIT TTM for ALNY.
Start Your YCharts Pro Gold Membership.
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
YCharts Pro is only $49/month, and comes with a 14-day free trial.Get Started Now
Already a YCharts Pro Gold Member? Sign in here.
ALNY EV / EBIT TTM Benchmarks
|Tekmira Pharmaceuticals Corporation||Go Pro|
|Vertex Pharmaceuticals||Go Pro|
Fool Jun 17
Street Insider Jun 11